--- title: "Insmed Insiders Sold Shares Worth Over $3.2M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286609887.md" description: "Insmed executives sold shares totaling over $3.2 million. CEO William Lewis sold 13,283 shares for $1.54 million, CFO Sara Bonstein sold 8,272 shares for $961,040, and COO Roger Adsett sold 5,837 shares for $678,142, all to cover tax obligations and broker fees. Post-transactions, Lewis holds 287,902 shares, Bonstein 71,486 shares, and Adsett 100,973 shares." datetime: "2026-05-15T20:20:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286609887.md) - [en](https://longbridge.com/en/news/286609887.md) - [zh-HK](https://longbridge.com/zh-HK/news/286609887.md) --- # Insmed Insiders Sold Shares Worth Over $3.2M William Lewis, a director and the Chair and CEO, sold 13,283 shares of common stock at $116.18 per share to satisfy tax withholding on vested restricted stock units and related broker fees for a total sale amount of $1,543,218; following the transaction, Lewis directly owned 287,902 shares and indirectly owned 233,924 shares held by a trust. Sara Bonstein, an officer serving as Chief Financial Officer, sold 8,272 shares of common stock at $116.18 per share on May 13, 2026 to satisfy tax withholding obligations upon the vesting of restricted stock units and to cover related broker fees for a total sale amount of $961,040; after the transaction, Bonstein directly owned 71,486 shares of common stock. Roger Adsett, an officer serving as Chief Operating Officer, sold 5,837 shares of common stock at $116.18 per share to satisfy tax withholding obligations and cover related broker fees for a total sale amount of $678,142; following the transaction, Adsett directly beneficially owned 100,973 shares of common stock. Reporter Name Relationship Type Amount SEC Filing Lewis William Chair and CEO Sell $1,543,218 Form 4 Bonstein Sara Chief Financial Officer Sell $961,040 Form 4 Adsett Roger Chief Operating Officer Sell $678,142 Form 4 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [INSM.US](https://longbridge.com/en/quote/INSM.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BKIV.US](https://longbridge.com/en/quote/BKIV.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [PTH.US](https://longbridge.com/en/quote/PTH.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus](https://longbridge.com/en/news/286727771.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md) - [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)